Sernova Corp. (SEOVF)
USD 0.13
(0.32%)
USD 0.13
(0.32%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -445.55 Thousand CAD | -1.26% |
| 2022 | -439.99 Thousand CAD | -64.67% |
| 2021 | -267.2 Thousand CAD | -18.64% |
| 2020 | -225.23 Thousand CAD | -266.38% |
| 2019 | -61.47 Thousand CAD | 4.73% |
| 2018 | -64.52 Thousand CAD | -61.86% |
| 2017 | -39.86 Thousand CAD | -427.05% |
| 2016 | -7564.00 CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | -100.0% |
| 2005 | 5284.00 CAD | -88.07% |
| 2004 | 44.27 Thousand CAD | -66.64% |
| 2003 | 132.74 Thousand CAD | 685.65% |
| 2002 | 16.89 Thousand CAD | -79.22% |
| 2001 | 81.32 Thousand CAD | 0.0% |
| 2000 | - CAD | 0.0% |
| 1999 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -104.25 Thousand CAD | 13.37% |
| 2024 Q2 | -102.79 Thousand CAD | 1.4% |
| 2024 Q3 | - CAD | 100.0% |
| 2023 Q4 | -120.33 Thousand CAD | -9.82% |
| 2023 Q3 | -109.57 Thousand CAD | -0.84% |
| 2023 Q2 | -108.66 Thousand CAD | 57.45% |
| 2023 Q1 | -255.35 Thousand CAD | -117.1% |
| 2023 FY | -445.55 Thousand CAD | -1.26% |
| 2022 Q2 | -112.01 Thousand CAD | 60.13% |
| 2022 FY | -439.99 Thousand CAD | -64.67% |
| 2022 Q3 | -116.61 Thousand CAD | -4.11% |
| 2022 Q4 | -117.62 Thousand CAD | -0.86% |
| 2022 Q1 | -280.94 Thousand CAD | -231.52% |
| 2021 Q1 | - CAD | 0.0% |
| 2021 Q4 | -84.74 Thousand CAD | -38.44% |
| 2021 Q3 | -61.21 Thousand CAD | -0.9% |
| 2021 FY | -267.2 Thousand CAD | -18.64% |
| 2021 Q2 | -60.66 Thousand CAD | 0.0% |
| 2020 Q1 | - CAD | 0.0% |
| 2020 Q3 | - CAD | 0.0% |
| 2020 Q4 | - CAD | 0.0% |
| 2020 FY | -225.23 Thousand CAD | -266.38% |
| 2020 Q2 | - CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2019 FY | -61.47 Thousand CAD | 4.73% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 Q4 | - CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2018 FY | -64.52 Thousand CAD | -61.86% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 FY | -39.86 Thousand CAD | -427.05% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 FY | -7564.00 CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q1 | - CAD | 100.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 100.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | -558.00 CAD | 0.0% |
| 2009 Q3 | 12.88 Thousand CAD | 139.99% |
| 2009 Q2 | 5369.00 CAD | -58.51% |
| 2009 Q1 | 12.94 Thousand CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q4 | -27.49 Thousand CAD | -313.38% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2006 Q3 | 35.48 Thousand CAD | 0.0% |
| 2006 Q2 | - CAD | 0.0% |
| 2006 Q1 | - CAD | 0.0% |
| 2006 Q4 | - CAD | -100.0% |
| 2006 FY | - CAD | -100.0% |
| 2005 FY | 5284.00 CAD | -88.07% |
| 2005 Q3 | 18.56 Thousand CAD | 1993.35% |
| 2005 Q4 | - CAD | -100.0% |
| 2005 Q1 | 1087.00 CAD | 183.49% |
| 2005 Q2 | 887.00 CAD | -18.4% |
| 2004 Q4 | -1302.00 CAD | -101.55% |
| 2004 Q2 | 1333.00 CAD | -67.64% |
| 2004 FY | 44.27 Thousand CAD | -66.64% |
| 2004 Q3 | 83.85 Thousand CAD | 6190.92% |
| 2004 Q1 | 4119.00 CAD | -81.98% |
| 2003 Q3 | 105.73 Thousand CAD | 3820.58% |
| 2003 FY | 132.74 Thousand CAD | 685.65% |
| 2003 Q2 | 2697.00 CAD | 86.51% |
| 2003 Q1 | 1446.00 CAD | -48.54% |
| 2003 Q4 | 22.86 Thousand CAD | -78.38% |
| 2002 Q2 | 2742.00 CAD | -66.69% |
| 2002 Q1 | 8231.00 CAD | 0.0% |
| 2002 Q4 | 2810.00 CAD | -9.73% |
| 2002 FY | 16.89 Thousand CAD | -79.22% |
| 2002 Q3 | 3113.00 CAD | 13.53% |
| 2001 FY | 81.32 Thousand CAD | 0.0% |
| 2000 FY | - CAD | 0.0% |
| 1999 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 9.61 Million USD | 104.636% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -258.589% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.374% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -39.45% |
| Qrons Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -823.25% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -18167.774% |
| BioStem Technologies, Inc. | 15.42 Million USD | 102.889% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 352.351% |
| CSL Limited | 7.56 Billion USD | 100.006% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 98.273% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 103.806% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 417.118% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 102.971% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 14463.346% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 104.549% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 777.871% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -1204.688% |
| Mesoblast Limited | -35.16 Million USD | 98.733% |
| Marizyme, Inc. | 457.7 Thousand USD | 197.345% |
| Genus plc | 178.7 Million USD | 100.249% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.202% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 816.021% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 208.627% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -3950.464% |
| ContraFect Corporation | -154 Thousand USD | -189.319% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -791.102% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 680.439% |
| IMV Inc. | -962.29 Thousand USD | 53.699% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -14.981% |
| MultiCell Technologies, Inc. | 49.32 USD | 903488.078% |
| ONE Bio Corp. | 20.12 Million USD | 102.214% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 101.107% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 1011.147% |
| Q BioMed Inc. | -8988.00 USD | -4857.176% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 101.577% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -2788.686% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 101.004% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 60.97% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 736.501% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -8897.395% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -356.905% |
| GB Sciences, Inc. | -624.00 USD | -71302.404% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -417.914% |
| HST Global, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -214107.212% |
| Enzolytics Inc. | 30.7 Thousand USD | 1550.928% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 192.355% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.04% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 13.403% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 172.168% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.109% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -4931.064% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -431.373% |
| Kadimastem Ltd | -630.13 Thousand USD | 29.293% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 145.097% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -3664.689% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 352.351% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 132.83% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -1436.383% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 199.002% |
| SYBLEU INC | 11.69 Thousand USD | 3909.431% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 109.669% |
| Bioxytran, Inc. | -8285.00 USD | -5277.803% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -19.451% |
| Neutra Corp. | 14.33 Thousand USD | 3208.134% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -443.355% |
| PureTech Health plc | -1.6 Million USD | 72.205% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 55.5% |
| IXICO plc | 3.27 Million USD | 113.625% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 35.8% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 75.123% |
| CSL Limited | 7.7 Billion USD | 100.006% |
| Cellectis S.A. | 18 Thousand USD | 2575.283% |